Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 19/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 15/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 13/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | TSPO | P30536 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875599 | 0.82 | CHRM3 (0.43) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL20476343 | 0.79 | CHRM3 (0.55) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1872475 | 0.79 | MAPT (0.46) | CHRM3CHRM2CHRM1HRH1KCNH2 | |
| Acetic Acid SCHEMBL20476349 | 0.78 | CHRM3 (0.54) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1877298 | 0.74 | CES2 (0.44) | — | |
| SCHEMBL5961630 | 0.73 | KMT2A (0.40) | — | |
| SCHEMBL14019158 | 0.73 | CHRM3 (0.58) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL26529380 | 0.71 | CHRM3 (0.47) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL25907223 | 0.71 | CHRM3 (0.47) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL28465528 | 0.71 | CHRM3 (0.52) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947730-B2 | Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic M3 receptor | NOVARTIS AG (CH) | 2011-05-24 | — | — | US | disclosed |
| US-20060287362-A1 | Organic compounds | NOVARTIS AG (CH) | 2006-12-21 | — | — | US | disclosed |
| EP-1638940-A2 | PIPERIDINIUM AND PYRROLIDINIUM DERIVATIVES AS LIGANDS FOR THE MUSCARINIC M3 RECEPTOR | Novartis AG (CH) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000815-A2 | PIPERIDINIUM AND PYRROLIDINIUM DERIVATIVES AS LIGANDS FOR THE MUSCARINIC M3 RECEPTOR | NOVARTIS AG (CH) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287362-A1 | Organic compounds | CHRM2, CHRM3, CHRM1 | CHRM3 2/4885CHRM2 1/4885CHRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.